Biomarin Pharmaceutical Inc
BMRN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001048477
In the last 90 days, Biomarin Pharmaceutical Inc insiders filed 0 open-market purchases and 1 sale; 565 institutions reported holding it in 13F filings for Q2 2026, worth $11.1B in total; Viking Global Investors is the only superinvestor holding it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.16M in total
- 1
- 13F holdersQ2 2026, +10 vs. previous quarter
- 565
- 13F valueReported value at the end of Q2 2026
- $11.1B
- Superinvestors holdingAt the end of Q2 2026
- 1
Price chart
Superinvestors holding BMRN, Q2 2026
1 superinvestor reports holding Biomarin Pharmaceutical Inc on Form 13F. Percentages are the stock's share of each portfolio.
Viking Global Investors
Andreas Halvorsen
1.2%
Biomarin Pharmaceutical Inc's share of the portfolio
- Shares
- 7,616,563
- Value
- $435.8M
Latest insider trades
Open-market purchases and sales by Biomarin Pharmaceutical Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)6:41 PM ET | Sep 2 | 1 day | Davis George EricEVP, Chief Legal Officer | SSale | −17.6K | $66.28 | −$1.16M | −22.3%61.0K after | |
| May 11, 2026 (view filing) | May 7 | 4 days | Friberg Gregory REVP, Chief R&D Officer | SSale | −3.28K | $53.85 | −$176.7K | −6.0%51.8K after | |
| Mar 12, 2026 (view filing) | Mar 11 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −16.5K | $60.46 | −$996.7K | −17.1%80.0K after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Friberg Gregory REVP, Chief R&D Officer | SSale | −6.33K | $60.38 | −$382.0K | −14.4%37.6K after | |
| Feb 26, 2026 (view filing) | Feb 26 | Same day | Davis George EricEVP, Chief Legal Officer | SSale | −26.1K | $61.36 | −$1.60M | −26.5%72.5K after | |
| May 20, 2025 (view filing) | May 20 | Same day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.79K | $59.31 | −$105.9K | −11.2%14.2K after | 10b5-1 |
| May 6, 2025 (view filing) | May 2 | 4 days | Hubbard CristinEVP, Chief Commercial Officer | SSale | −273 | $64.92 | −$17.7K | −0.8%32.7K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 19 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.29K | $71.52 | −$92.6K | −7.1%17.0K after | 10b5-1 |
| Mar 7, 2025 (view filing) | Mar 6 | 1 day | Guyer Charles GregEVP, Chief Technical Officer | SSale | −7.03K | $71.28 | −$501.4K | −7.4%87.7K after | |
| Feb 25, 2025 (view filing) | Feb 24 | 1 day | Burkhart ErinGVP, Chief Accounting Officer | SSale | −1.34K | $68.38 | −$91.9K | −9.3%13.1K after | 10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Biomarin Pharmaceutical Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 20,445,212 | $1.17B | 0.02% | +626,911+3.2% | Added |
| Dodge & Cox | 14,844,930 | $849.4M | 0.44% | +283,171+1.9% | Added |
| Primecap Management Co | 14,190,183 | $812.0M | 0.48% | −3,8220.0% | Reduced |
| Vanguard Capital Management LLC | 8,743,633 | $500.3M | 0.01% | +100,469+1.2% | Added |
| Vanguard Portfolio Management LLC | 8,648,678 | $494.9M | 0.02% | +350,203+4.2% | Added |
| Norges Bank | 8,207,954 | $469.7M | 0.05% | +8,207,954 | New |
| State Street Corp | 7,800,959 | $446.4M | 0.01% | +505,880+6.9% | Added |
| Viking Global Investors LPSuperinvestorViking Global Investors | 7,616,563 | $435.8M | 1.24% | +554,486+7.9% | Added |
| Vestal Point Capital, LP | 6,025,000 | $344.8M | 8.06% | +2,450,000+68.5% | Added |
| AQR Capital Management LLC | 5,699,541 | $322.5M | 0.11% | −1,977,000−25.8% | Reduced |